Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The SUGAR-MGH investigators are studying the influence of inherited gene variants on the
response to two commonly prescribed type 2 diabetes medications, metformin and glipizide.
They hypothesize that variants in genes that are associated with type 2 diabetes or related
traits may impact the effect of anti-diabetic medications. In addition, physiological
responses to an insulin secretagogue or an insulin sensitizer may shed light on the mechanism
of action of reported genetic associations.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Broad Institute Joslin Diabetes Center